Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Detroit, Michigan

This page shows live ClinicalTrials.gov search results for Detroit, Michigan, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7248
Shown on this page
12
Current sort
Recently updated
Location scope
Detroit, MI
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Detroit, Michigan. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 721–732 of 7,248 matching trials in Detroit, MI.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Active, not recruiting Phase 3 Interventional

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

NCT05984277
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Hot Springs, Arkansas • Springdale, Arkansas • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 15, 2026, 5:22 AM EST
Completed Phase 3 Interventional

Study of Bitopertin in Participants With EPP or XLP (APOLLO)

NCT06910358
View directory record Official record
Conditions
Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Interventions
Placebo, DISC-1459
Drug
Lead sponsor
Disc Medicine, Inc
Industry
Eligibility
12 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
11
States / cities
Huntington Beach, California • San Francisco, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 15, 2026, 5:22 AM EST
Active, not recruiting Phase 3 Interventional

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

NCT05899608
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Ivonescimab Injection, Pembrolizumab Injection
Biological
Lead sponsor
Summit Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
76
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 15, 2026, 5:22 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

NCT06292013
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Interventions
Lepodisiran Sodium, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
17,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
222
States / cities
Birmingham, Alabama • Daphne, Alabama • Dothan, Alabama + 171 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 15, 2026, 5:22 AM EST
Completed Phase 3 Interventional

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

NCT03924856
View directory record Official record
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Gemcitabine, Cisplatin, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Placebo
Drug · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
907 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
24
States / cities
La Jolla, California • Santa Monica, California • Washington D.C., District of Columbia + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 15, 2026, 5:22 AM EST
Completed Phase 3 Interventional

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

NCT03847428
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Durvalumab, Bevacizumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 150 Years
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
34
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 15, 2026, 5:22 AM EST
Active, not recruiting Phase 3 Interventional

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

NCT03148418
View directory record Official record
Conditions
Cancer
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
44
States / cities
Scottsdale, Arizona • Los Angeles, California • San Marcos, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 15, 2026, 5:22 AM EST
Recruiting Phase 2 Interventional

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

NCT06699849
View directory record Official record
Conditions
Sickle Cell Disease Vaso-occlusive Crisis
Interventions
CSL889, Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Oakland, California • Orange, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 15, 2026, 5:22 AM EST
Recruiting Phase 1 Interventional

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06673017
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions
PTM-101
Drug
Lead sponsor
PanTher Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Newport Beach, California • Miami, Florida • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 15, 2026, 5:22 AM EST
Recruiting Phase 1Phase 2 Interventional

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

NCT05850234
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
AZD0120
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 15, 2026, 5:22 AM EST
Recruiting Phase 3 Interventional

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

NCT07768189
View directory record Official record
Conditions
Oropharyngeal Carcinoma (OPC)
Interventions
CRB-701, capcitabine, Cetuximab (EGFR inhibitor), Docetaxel
Drug
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
38
States / cities
Huntsville, Alabama • Tucson, Arizona • Duarte, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 15, 2026, 5:22 AM EST
Recruiting Phase 2 Interventional

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

NCT07589608
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Macupatide, Eloralintide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 15, 2026, 5:22 AM EST